Kittel, C. (2017). Vacthera BioTech : business plan for a Biotech startup company [Master Thesis, Technische Universität Wien; Wirtschaftsuniversität Wien]. reposiTUm. http://hdl.handle.net/20.500.12708/78390
Business Plan; Biotech; Vaccines; Influenza; Oncology
de
Abstract:
Vacthera is a biotechnology company developing influenza virus based vaccines and cancer immunotherapies. Vacthera¿s patented platform technology allows genetic modification of the influenza virus to be used as safe but efficient prophylactic vaccines against various diseases or as therapeutic vaccines against cancer. Although this platform technology allows generation of vaccines for a number of infectious diseases including influenza, RSV, herpes or tuberculosis (unpublished), Vacthera intends to undergo first preclinical development for two initial products, namely a universal influenza vaccine and an oncolytic virus. UniFluVec is a universal influenza vaccine allowing the efficient protection against various influenza types and subtypes. OncoFluVec is an anti¿cancer vaccine (oncolytic influenza virus) allowing immunological destruction of cancers. Both products will be produced to high yields in embryonated chicken eggs and purified by a Vacthera¿s proprietary technology.